Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:academic_advisor |
Advisors from leading universities.
|
| gptkbp:acquisition |
Sana Biotechnology acquired the rights to a gene therapy platform.
|
| gptkbp:awards |
Recognized for innovation in biotechnology.
|
| gptkbp:ceo |
Steve Harr
|
| gptkbp:challenges |
Facing challenges in regulatory processes.
|
| gptkbp:clinical_trial |
Conducting clinical trials for various therapies.
Engaged in clinical research. |
| gptkbp:collaboration |
Collaborating with research institutions.
Working with pharmaceutical companies. |
| gptkbp:community_engagement |
Involved in community health initiatives.
|
| gptkbp:conference |
Participates in biotechnology conferences.
|
| gptkbp:focus |
gptkb:gene_therapy
cell engineering |
| gptkbp:founded |
gptkb:2018
|
| gptkbp:founder |
Steve Harr
|
| gptkbp:funding |
Raised over $300 million in funding.
Secured significant research funding. |
| gptkbp:future_plans |
Exploring international markets.
Enhancing partnerships with biotech firms. Expanding research and development efforts. Investing in advanced technologies. Launching new clinical trials. |
| gptkbp:goal |
Addressing unmet medical needs.
Creating therapies for cancer. Developing treatments for genetic diseases. |
| gptkbp:headquarters |
gptkb:Seattle,_Washington
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sana Biotechnology
|
| gptkbp:impact |
Aiming to have a significant impact on healthcare.
|
| gptkbp:innovation |
Pioneering new approaches in cell therapy.
|
| gptkbp:invention |
Holds multiple patents in biotechnology.
|
| gptkbp:investment |
Venture capital firms.
|
| gptkbp:key_people |
gptkb:Katherine_A._High
gptkb:Mark_A._Kay gptkb:David_A._Schaffer |
| gptkbp:location |
United States.
|
| gptkbp:mission |
Transforming the lives of patients through engineered cells.
|
| gptkbp:network |
Engages in networking with industry leaders.
|
| gptkbp:number_of_employees |
Over 100 employees.
|
| gptkbp:partnership |
Partnership with various academic institutions.
|
| gptkbp:product |
Sana-001.
Sana-002. Sana-003. Sana-004. Sana-005. |
| gptkbp:publications |
Published research in scientific journals.
|
| gptkbp:regulatory_compliance |
Seeking FDA approval for therapies.
|
| gptkbp:research_focus |
Advancing gene editing technologies.
Creating cell therapies for diseases. Developing engineered cells for therapeutic purposes. |
| gptkbp:stock_symbol |
SANA
|
| gptkbp:subsidiary |
Sana Therapeutics.
|
| gptkbp:sustainability |
Focus on sustainable practices.
|
| gptkbp:technology |
Cell and gene therapy technologies.
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:vision |
To be a leader in cell and gene therapy.
|
| gptkbp:website |
https://sanabiotechnology.com
|
| gptkbp:bfsParent |
gptkb:Cure_Vac
|
| gptkbp:bfsLayer |
4
|